These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 23113655

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 4. [The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
    Togo Y, Shimatani K, Hanasaki T, Yo T, Nakanishi Y, Nagasawa S, Hashimoto T, Shiraishi Y, Taoka R, Suzuki T, Go S, Higuchi Y, Kanematsu A, Nojima M, Tsuchihashi K, Makino Y, Shimizu Y, Kanamaru S, Kono Y, Matsumoto K, Utsunomiya N, Ito N, Kawakita M, Yamamoto S.
    Hinyokika Kiyo; 2014 May; 60(5):209-14. PubMed ID: 24894855
    [Abstract] [Full Text] [Related]

  • 5. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.
    JAMA; 2006 Jun 07; 295(21):2516-24. PubMed ID: 16757724
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS, Wu X, Zhao PJ, Huang LH, Song Y, Gong K, Shen C, Yu W, Song G, Zhao Z, Zhang Z, Zhang Q, Wang G, He ZS, Zhou LQ, Jin J.
    Chin Med J (Engl); 2011 Sep 07; 124(18):2920-4. PubMed ID: 22040503
    [Abstract] [Full Text] [Related]

  • 14. [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
    Thiery-Vuillemin A, Mouillet G, Pouessel D, Barthelemy P, Caty A, Sebbagh S, Vanno YA, Laplaige P, Cheverau C, Ravaud A.
    Bull Cancer; 2014 Sep 07; 101(9):832-40. PubMed ID: 25295955
    [Abstract] [Full Text] [Related]

  • 15. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
    Najjar YG, Mittal K, Elson P, Wood L, Garcia JA, Dreicer R, Rini BI.
    Eur J Cancer; 2014 Apr 07; 50(6):1084-9. PubMed ID: 24559686
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
    Miyake H, Harada K, Miyazaki A, Fujisawa M.
    Med Oncol; 2015 Mar 07; 32(3):78. PubMed ID: 25698532
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.